| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0305-7372(10)70023-2 |
| P698 | PubMed publication ID | 21129614 |
| P50 | author | Nicola Fazio | Q42719569 |
| Evaristo Maiello | Q54343946 | ||
| P2093 | author name string | L Orlando | |
| A Marino | |||
| M D'Amico | |||
| G Colucci | |||
| A Nacci | |||
| N Silvestris | |||
| S Cinieri | |||
| P Schiavone | |||
| E Mazzoni | |||
| P Rizzo | |||
| P Fedele | |||
| N Calvani | |||
| F Sponziello | |||
| M Cinefra | |||
| P2860 | cites work | An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors | Q28207289 |
| Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials | Q29547513 | ||
| Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer | Q29547699 | ||
| ERbeta in breast cancer--onlooker, passive player, or active protector? | Q30438399 | ||
| Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial | Q33386922 | ||
| Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region. | Q34046421 | ||
| Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer | Q34110074 | ||
| Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice. | Q34177001 | ||
| Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer | Q34181456 | ||
| Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. | Q34382805 | ||
| Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial | Q34440858 | ||
| Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer | Q35191033 | ||
| Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer | Q35583927 | ||
| Targeting oestrogen to kill the cancer but not the patient | Q35680855 | ||
| Oestrogen receptors and selective oestrogen receptor modulators: molecular and cellular pharmacology. | Q36018567 | ||
| Estrogen-receptor biology: continuing progress and therapeutic implications | Q36065443 | ||
| Aromatase inhibitors: future directions | Q36194354 | ||
| Identification and mechanisms of endocrine resistance | Q37039796 | ||
| Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover | Q37599824 | ||
| Cross-talk between non-genomic and genomic signalling pathways--distinct effect profiles of environmental estrogens | Q39731649 | ||
| Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention | Q39743511 | ||
| Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer | Q40544950 | ||
| Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer | Q43136784 | ||
| Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. | Q43286764 | ||
| Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer? | Q43287052 | ||
| Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial | Q43595450 | ||
| Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators | Q43988923 | ||
| Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials | Q44519633 | ||
| A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer | Q44795543 | ||
| Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial | Q44875574 | ||
| A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer | Q46586619 | ||
| Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial | Q46786144 | ||
| Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial | Q57961780 | ||
| Tamoxifen in the treatment of breast cancer | Q77598704 | ||
| Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole | Q83930167 | ||
| Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM | Q84592604 | ||
| P304 | page(s) | S67-71 | |
| P577 | publication date | 2010-11-01 | |
| P1433 | published in | Cancer Treatment Reviews | Q1955762 |
| P1476 | title | Molecularly targeted endocrine therapies for breast cancer | |
| P478 | volume | 36 Suppl 3 |
| Q57975741 | A Minimal Functional Complex of Cytochrome P450 and FBD of Cytochrome P450 Reductase in Nanodiscs |
| Q30633058 | A model of the membrane-bound cytochrome b5-cytochrome P450 complex from NMR and mutagenesis data. |
| Q35141461 | A steroid-conjugated magnetic resonance probe enhances contrast in progesterone receptor expressing organs and tumors in vivo |
| Q64906486 | Aberrant expression of SETD1A promotes survival and migration of estrogen receptor α-positive breast cancer cells. |
| Q36800401 | Acting on Hormone Receptors with Minimal Side Effect on Cell Proliferation: A Timely Challenge Illustrated with GLP-1R and GPER |
| Q33989913 | Adeno-associated virus type 2 infection of nude mouse human breast cancer xenograft induces necrotic death and inhibits tumor growth |
| Q35155456 | Altered Endoplasmic Reticulum Calcium Pump Expression during Breast Tumorigenesis |
| Q97636619 | CXCR4 Antagonist AMD3100 Reverses the Resistance to Tamoxifen in Breast Cancer via Inhibiting AKT Phosphorylation |
| Q38067765 | Chromatin landscape and endocrine response in breast cancer. |
| Q64249317 | Clinical and Biological Significance of Gene Alteration and Estrogen Receptors Isoforms Expression in Breast Cancer Patients |
| Q41520280 | Cryptotanshinone inhibition of mammalian target of rapamycin pathway is dependent on oestrogen receptor alpha in breast cancer |
| Q54584474 | ERasing breast cancer resistance through the kinome. |
| Q38012175 | Epigenetics of estrogen receptor-negative primary breast cancer |
| Q33817324 | Estrogen regulation of anti-apoptotic Bcl-2 family member Mcl-1 expression in breast cancer cells |
| Q35795751 | International Union of Basic and Clinical Pharmacology. XCVII. G Protein-Coupled Estrogen Receptor and Its Pharmacologic Modulators |
| Q41353184 | Kinetic and Structural Characterization of the Effects of Membrane on the Complex of Cytochrome b 5 and Cytochrome c. |
| Q38053130 | Long-range transcriptional regulation of breast cancer genes |
| Q33909044 | Mediator and human disease |
| Q39431604 | Melatonin interferes in the desmoplastic reaction in breast cancer by regulating cytokine production |
| Q42808778 | Melatonin promotes differentiation of 3T3-L1 fibroblasts. |
| Q37376167 | Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation. |
| Q38842969 | Personalized in vitro cancer models to predict therapeutic response: Challenges and a framework for improvement |
| Q30836342 | Progesterone-targeted magnetic resonance imaging probes |
| Q34040411 | Synthesis and biological evaluation of water-soluble progesterone-conjugated probes for magnetic resonance imaging of hormone related cancers |
| Q27013052 | The G-protein-coupled estrogen receptor GPER in health and disease |
| Q36735733 | The Predominant Proteins that React to the MC-20 Estrogen Receptor Alpha Antibody Differ in Molecular Weight between the Mammary Gland and Uterus in the Mouse and Rat. |
| Q35684410 | The Role of Interferon Regulatory Factor-1 (IRF1) in Overcoming Antiestrogen Resistance in the Treatment of Breast Cancer. |
| Q39401164 | The relationships between snail1 and estrogen receptor signaling in breast cancer cells. |
| Q34485765 | What have we learned about GPER function in physiology and disease from knockout mice? |
Search more.